{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:40:31Z","timestamp":1790404831966,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Excellent Grant of Comenius University Bratislava 2024","award":["UK\/3096\/2024"],"award-info":[{"award-number":["UK\/3096\/2024"]}]},{"DOI":"10.13039\/501100003193","name":"Ministerstvo \u0161kolstva, vedy, v\u00fdskumu a \u0161portu Slovenskej republiky","doi-asserted-by":"publisher","award":["1\/0513\/24"],"award-info":[{"award-number":["1\/0513\/24"]}],"id":[{"id":"10.13039\/501100003193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003193","name":"Ministerstvo \u0161kolstva, vedy, v\u00fdskumu a \u0161portu Slovenskej republiky","doi-asserted-by":"publisher","award":["1\/0121\/22"],"award-info":[{"award-number":["1\/0121\/22"]}],"id":[{"id":"10.13039\/501100003193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-23-0399"],"award-info":[{"award-number":["APVV-23-0399"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005357","name":"Agent\u00fara na Podporu V\u00fdskumu a V\u00fdvoja","doi-asserted-by":"publisher","award":["APVV-23-0502"],"award-info":[{"award-number":["APVV-23-0502"]}],"id":[{"id":"10.13039\/501100005357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007594","name":"Comenius University in Bratislava","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007594","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diabetic nephropathy (DN) is currently a leading cause of end-stage renal disease. Both dapagliflozin and pioglitazone have shown protective effects on organ damage in diabetes, even beyond their blood glucose-lowering properties. This study aimed to assess whether the simultaneous activation of PPAR\u03b3 and inhibition of SGLT2 cotransporters provide additive protection against inflammation and fibrosis which are highly engaged in the progression of DN in experimental type 1 diabetes mellitus. Diabetes was induced in Wistar rats using streptozotocin (55\u00a0mg\/kg, i.p.), and the animals received daily chow containing dapagliflozin (10\u00a0mg\/kg), pioglitazone (12\u00a0mg\/kg), or their combination. Six weeks after streptozotocin administration, molecular, histological and immunohistochemical analyses were performed in the excised kidneys. In the kidneys of diabetic rats, disruption of renal function markers was accompanied by increased macrophage infiltration and collagen deposition. Both pioglitazone and dapagliflozin decreased proinflammatory markers expression (IL1b, IL6, Cox2, Tnf\u03b1) and CD68-positive areas. Both monotherapies positively modulated Tgf\u03b2, HGF and Agtr1 expression, leading to fibrosis reduction and morphological normalisation. Similarly to pioglitazone, the combined therapy reduced \u03b1-SMA-positive areas. Despite an additive antihypertensive effect, the combination maximally reached the effect of the monotherapies in other measured parameters. Overall, both dapagliflozin and pioglitazone are renoprotective in monotherapy, but their combination does not provide additional benefits in reducing inflammation, fibrosis or restoring kidney function.\u00a0<\/jats:p>","DOI":"10.1007\/s00210-025-04613-x","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T21:56:29Z","timestamp":1758923789000},"page":"3001-3015","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined dapagliflozin and pioglitazone therapy in diabetic nephropathy: no added benefit beyond monotherapy in inflammation and fibrosis"],"prefix":"10.1007","volume":"399","author":[{"given":"Cinakova","family":"A","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vavrincova-Yaghi","family":"D","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vavrinec","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krenek","family":"P","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klimas","family":"J","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8993-9011","authenticated-orcid":false,"given":"Kralova","family":"E.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"4613_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174715","volume":"918","author":"E Abdollahi","year":"2022","unstructured":"Abdollahi E, Keyhanfar F, Delbandi A-A et al (2022) Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages. Eur J Pharmacol 918:174715. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174715","journal-title":"Eur J Pharmacol"},{"key":"4613_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.bbrc.2018.02.055","volume":"497","author":"Y Amano","year":"2018","unstructured":"Amano Y, Tsuchiya S, Imai M et al (2018) Combination effects of alogliptin and pioglitazone on steatosis and hepatic fibrosis formation in a mouse model of non-alcoholic steatohepatitis. Biochem Biophys Res Commun 497:207\u2013213. https:\/\/doi.org\/10.1016\/j.bbrc.2018.02.055","journal-title":"Biochem Biophys Res Commun"},{"key":"4613_CR3","doi-asserted-by":"publisher","first-page":"180270","DOI":"10.1155\/2014\/180270","volume":"2014","author":"K Braga Gomes","year":"2014","unstructured":"Braga Gomes K, Fontana Rodrigues K, Fernandes AP (2014) The role of transforming growth factor-beta in diabetic nephropathy. Int J Med Genet 2014:180270. https:\/\/doi.org\/10.1155\/2014\/180270","journal-title":"Int J Med Genet"},{"key":"4613_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1053\/ajkd.2000.16192","volume":"36","author":"KD Burns","year":"2000","unstructured":"Burns KD (2000) Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis 36:449\u2013467. https:\/\/doi.org\/10.1053\/ajkd.2000.16192","journal-title":"Am J Kidney Dis"},{"key":"4613_CR5","doi-asserted-by":"publisher","first-page":"1205834","DOI":"10.3389\/fimmu.2023.1205834","volume":"14","author":"A Cai","year":"2023","unstructured":"Cai A, Shen J, Yang X et al (2023) Dapagliflozin alleviates renal inflammation and protects against diabetic kidney diseases, both dependent and independent of blood glucose levels. Front Immunol 14:1205834. https:\/\/doi.org\/10.3389\/fimmu.2023.1205834","journal-title":"Front Immunol"},{"key":"4613_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000505144","volume":"51","author":"G Castoldi","year":"2020","unstructured":"Castoldi G, Carletti R, Ippolito S et al (2020) Renal anti-fibrotic effect of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension. Am J Nephrol 51:119\u2013129. https:\/\/doi.org\/10.1159\/000505144","journal-title":"Am J Nephrol"},{"key":"4613_CR7","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.ymthe.2022.08.013","volume":"31","author":"J Chen","year":"2023","unstructured":"Chen J, Tang T-T, Cao J-Y et al (2023) KIM-1 augments hypoxia-induced tubulointerstitial inflammation through uptake of small extracellular vesicles by tubular epithelial cells. Mol Ther 31:1437\u20131450. https:\/\/doi.org\/10.1016\/j.ymthe.2022.08.013","journal-title":"Mol Ther"},{"key":"4613_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1159\/000533592","volume":"108","author":"A Cinakova","year":"2023","unstructured":"Cinakova A, Krenek P, Klimas J, Kralova E (2023) Adding SGLT2 cotransporter inhibitor to PPAR\u03b3 activator does not provide an additive effect in the management of diabetes-induced vascular dysfunction. Pharmacology 108:565\u2013575. https:\/\/doi.org\/10.1159\/000533592","journal-title":"Pharmacology"},{"key":"4613_CR9","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1038\/s41598-024-84487-w","volume":"15","author":"A Cinakova","year":"2025","unstructured":"Cinakova A, Vavrincova-Yaghi D, Krenek P et al (2025) Combination of dapagliflozin and pioglitazone lacks superiority against monotherapy in streptozotocin-induced nephropathy. Sci Rep 15:1464. https:\/\/doi.org\/10.1038\/s41598-024-84487-w","journal-title":"Sci Rep"},{"key":"4613_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/br.2022.1584","volume":"18","author":"WB El Gazzar","year":"2023","unstructured":"El Gazzar WB, Allam MM, Shaltout SA et al (2023) Pioglitazone modulates immune activation and ameliorates inflammation induced by injured renal tubular epithelial cells via PPAR\u03b3\/miRNA-124\/STAT3 signaling. Biomedical Reports 18:1\u201310. https:\/\/doi.org\/10.3892\/br.2022.1584","journal-title":"Biomedical Reports"},{"key":"4613_CR11","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12882-021-02530-8","volume":"22","author":"Y-Z Feng","year":"2021","unstructured":"Feng Y-Z, Chen X-Q, Cheng Z-Y et al (2021) Non-invasive investigation of early kidney damage in streptozotocin-induced diabetic rats by intravoxel incoherent motion diffusion-weighted (IVIM) MRI. BMC Nephrol 22:321. https:\/\/doi.org\/10.1186\/s12882-021-02530-8","journal-title":"BMC Nephrol"},{"key":"4613_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.krcp.2013.01.003","volume":"32","author":"A Ghayur","year":"2013","unstructured":"Ghayur A, Margetts PJ (2013) Transforming growth factor-beta and the glomerular filtration barrier. Kidney Res Clin Pract 32:3\u201310. https:\/\/doi.org\/10.1016\/j.krcp.2013.01.003","journal-title":"Kidney Res Clin Pract"},{"key":"4613_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00412","author":"E Han","year":"2018","unstructured":"Han E, Shin E, Kim G et al (2018) Combining SGLT2 inhibition with a thiazolidinedione additively attenuate the very early phase of diabetic nephropathy progression in type 2 diabetes mellitus. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2018.00412","journal-title":"Front Endocrinol"},{"key":"4613_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.239","volume":"4","author":"T Hatanaka","year":"2016","unstructured":"Hatanaka T, Ogawa D, Tachibana H et al (2016) Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice. Pharmacol Res Perspect 4:e00239. https:\/\/doi.org\/10.1002\/prp2.239","journal-title":"Pharmacol Res Perspect"},{"key":"4613_CR15","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3389\/fimmu.2018.00893","volume":"9","author":"M Heming","year":"2018","unstructured":"Heming M, Gran S, Jauch S-L et al (2018) Peroxisome proliferator-activated receptor-\u03b3 modulates the response of macrophages to lipopolysaccharide and glucocorticoids. Front Immunol 9:893. https:\/\/doi.org\/10.3389\/fimmu.2018.00893","journal-title":"Front Immunol"},{"key":"4613_CR16","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1172\/JCI45361","volume":"123","author":"BD Humphreys","year":"2013","unstructured":"Humphreys BD, Xu F, Sabbisetti V et al (2013) Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest 123:4023\u20134035. https:\/\/doi.org\/10.1172\/JCI45361","journal-title":"J Clin Invest"},{"key":"4613_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/cphy.c120028","volume":"3","author":"JD Imig","year":"2013","unstructured":"Imig JD, Ryan MJ (2013) Immune and inflammatory role in renal disease. Compr Physiol 3:957\u2013976. https:\/\/doi.org\/10.1002\/cphy.c120028","journal-title":"Compr Physiol"},{"key":"4613_CR18","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S2211-9477(12)70006-7","volume":"1","author":"M Jain","year":"2012","unstructured":"Jain M (2012) Histopathological changes in diabetic kidney disease. Clinical Queries: Nephrology 1:127\u2013133. https:\/\/doi.org\/10.1016\/S2211-9477(12)70006-7","journal-title":"Clinical Queries: Nephrology"},{"key":"4613_CR19","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(21)00243-6","volume":"9","author":"N Jongs","year":"2021","unstructured":"Jongs N, Greene T, Chertow GM et al (2021) Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 9:755\u2013766. https:\/\/doi.org\/10.1016\/S2213-8587(21)00243-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4613_CR20","doi-asserted-by":"publisher","unstructured":"Kanasaki K, Taduri G, Koya D (2013) Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol 4:. https:\/\/doi.org\/10.3389\/fendo.2013.00007","DOI":"10.3389\/fendo.2013.00007"},{"key":"4613_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1463-1326.2010.01314.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Liu X, Shyu WC et al (2011) Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes Metab 13:47\u201354. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01314.x","journal-title":"Diabetes Obes Metab"},{"key":"4613_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051083","volume":"18","author":"D Kawanami","year":"2017","unstructured":"Kawanami D, Matoba K, Takeda Y et al (2017) SGLT2 inhibitors as a therapeutic option for diabetic nephropathy. Int J Mol Sci 18:1083. https:\/\/doi.org\/10.3390\/ijms18051083","journal-title":"Int J Mol Sci"},{"key":"4613_CR23","doi-asserted-by":"publisher","first-page":"992","DOI":"10.12669\/pjms.35.4.154","volume":"35","author":"FA Khan","year":"2019","unstructured":"Khan FA, Fatima SS, Khan GM, Shahid S (2019) Evaluation of kidney injury molecule-1 as a disease progression biomarker in diabetic nephropathy. Pak J Med Sci 35:992\u2013996. https:\/\/doi.org\/10.12669\/pjms.35.4.154","journal-title":"Pak J Med Sci"},{"key":"4613_CR24","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee S-G, Kim SH et al (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11:2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"key":"4613_CR25","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.3390\/pharmaceutics15071995","volume":"15","author":"J Klen","year":"2023","unstructured":"Klen J, Dol\u017ean V (2023) SGLT2 inhibitors in the treatment of diabetic kidney disease: more than just glucose regulation. Pharmaceutics 15:1995. https:\/\/doi.org\/10.3390\/pharmaceutics15071995","journal-title":"Pharmaceutics"},{"key":"4613_CR26","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1093\/ndt\/gfn157","volume":"23","author":"GJ Ko","year":"2008","unstructured":"Ko GJ, Kang YS, Han SY et al (2008) Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 23:2750\u20132760. https:\/\/doi.org\/10.1093\/ndt\/gfn157","journal-title":"Nephrol Dial Transplant"},{"key":"4613_CR27","doi-asserted-by":"publisher","first-page":"233","DOI":"10.2478\/rjim-2020-0023","volume":"58","author":"I Kostovska","year":"2020","unstructured":"Kostovska I, Trajkovska KT, Cekovska S et al (2020) Role of urinary podocalyxin in early diagnosis of diabetic nephropathy. Rom J Intern Med 58:233\u2013241. https:\/\/doi.org\/10.2478\/rjim-2020-0023","journal-title":"Rom J Intern Med"},{"key":"4613_CR28","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1093\/jpp\/rgab005","volume":"73","author":"E Kralova","year":"2021","unstructured":"Kralova E, Marusakova M, Hadova K et al (2021) Dapagliflozin elevates plasma high-density lipoprotein levels and influences visceral fat gene expression in streptozotocin-induced diabetes mellitus. J Pharm Pharmacol 73:778\u2013784. https:\/\/doi.org\/10.1093\/jpp\/rgab005","journal-title":"J Pharm Pharmacol"},{"key":"4613_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40200-021-00782-7","volume":"20","author":"S Kumari","year":"2021","unstructured":"Kumari S, Kamboj A, Wanjari M, Sharma AK (2021) Nephroprotective effect of vanillic acid in STZ-induced diabetic rats. J Diabetes Metab Disord 20:571\u2013582. https:\/\/doi.org\/10.1007\/s40200-021-00782-7","journal-title":"J Diabetes Metab Disord"},{"key":"4613_CR30","doi-asserted-by":"publisher","first-page":"F7","DOI":"10.1152\/ajprenal.00451.2003","volume":"287","author":"Y Liu","year":"2004","unstructured":"Liu Y (2004) Hepatocyte growth factor in kidney fibrosis: therapeutic potential and mechanisms of action. Am J Physiol-Renal Physiol 287:F7\u2013F16. https:\/\/doi.org\/10.1152\/ajprenal.00451.2003","journal-title":"Am J Physiol-Renal Physiol"},{"key":"4613_CR31","doi-asserted-by":"publisher","first-page":"110685","DOI":"10.1016\/j.diabres.2023.110685","volume":"200","author":"S-C Lo","year":"2023","unstructured":"Lo S-C, Kornelius E, Liao P-L et al (2023) Pioglitazone, SGLT2 inhibitors and their combination for primary prevention of cardiovascular disease and heart failure in type 2 diabetes: real-world evidence from a nationwide cohort database. Diabetes Res Clin Pract 200:110685. https:\/\/doi.org\/10.1016\/j.diabres.2023.110685","journal-title":"Diabetes Res Clin Pract"},{"key":"4613_CR32","doi-asserted-by":"publisher","first-page":"e0156346","DOI":"10.1371\/journal.pone.0156346","volume":"11","author":"G Luippold","year":"2016","unstructured":"Luippold G, Bedenik J, Voigt A, Grempler R (2016) Short- and longterm glycemic control of streptozotocin-induced diabetic rats using different insulin preparations. PLoS ONE 11:e0156346. https:\/\/doi.org\/10.1371\/journal.pone.0156346","journal-title":"PLoS ONE"},{"key":"4613_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242115520","volume":"24","author":"A Manz\u00e9ger","year":"2023","unstructured":"Manz\u00e9ger A, Garmaa G, M\u00f3zes MM et al (2023) Pioglitazone protects tubular epithelial cells during kidney fibrosis by attenuating miRNA dysregulation and autophagy dysfunction induced by TGF-\u03b2. Int J Mol Sci 24:15520. https:\/\/doi.org\/10.3390\/ijms242115520","journal-title":"Int J Mol Sci"},{"key":"4613_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/s1734-1140(12)70918-0","volume":"64","author":"RE Masoad","year":"2012","unstructured":"Masoad RE, Ewais MMS, Tawfik MK, Abd El-All HS (2012) Effect of mononuclear cells versus pioglitazone on streptozotocin-induced diabetic nephropathy in rats. Pharmacol Rep 64:1223\u20131233. https:\/\/doi.org\/10.1016\/s1734-1140(12)70918-0","journal-title":"Pharmacol Rep"},{"key":"4613_CR35","doi-asserted-by":"publisher","first-page":"13689","DOI":"10.1038\/s41598-019-49835-1","volume":"9","author":"B Medi\u0107","year":"2019","unstructured":"Medi\u0107 B, Stojanovi\u0107 M, Rov\u010danin B et al (2019) Pioglitazone attenuates kidney injury in an experimental model of gentamicin-induced nephrotoxicity in rats. Sci Rep 9:13689. https:\/\/doi.org\/10.1038\/s41598-019-49835-1","journal-title":"Sci Rep"},{"key":"4613_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","volume":"32","author":"DM Nathan","year":"2009","unstructured":"Nathan DM, Buse JB, Davidson MB et al (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32:193\u2013203. https:\/\/doi.org\/10.2337\/dc08-9025","journal-title":"Diabetes Care"},{"key":"4613_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-019-1431-x","volume":"20","author":"\u00c1 N\u00e9meth","year":"2019","unstructured":"N\u00e9meth \u00c1, M\u00f3zes MM, Calvier L et al (2019) The PPAR\u03b3 agonist pioglitazone prevents TGF-\u03b2 induced renal fibrosis by repressing EGR-1 and STAT3. BMC Nephrol 20:245. https:\/\/doi.org\/10.1186\/s12882-019-1431-x","journal-title":"BMC Nephrol"},{"key":"4613_CR38","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.biopha.2018.10.100","volume":"109","author":"MA Oraby","year":"2019","unstructured":"Oraby MA, El-Yamany MF, Safar MM et al (2019) Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. Biomed Pharmacother 109:910\u2013920. https:\/\/doi.org\/10.1016\/j.biopha.2018.10.100","journal-title":"Biomed Pharmacother"},{"key":"4613_CR39","doi-asserted-by":"publisher","DOI":"10.5114\/amsad\/151046","volume":"7","author":"GS Papaetis","year":"2022","unstructured":"Papaetis GS (2022) Pioglitazone in diabetic kidney disease: forgotten but not gone. Arch Med Sci Atheroscler Dis 7:e78\u2013e93. https:\/\/doi.org\/10.5114\/amsad\/151046","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"4613_CR40","doi-asserted-by":"publisher","first-page":"45e\u2013445","DOI":"10.1093\/nar\/29.9.e45","volume":"29","author":"MW Pfaffl","year":"2001","unstructured":"Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:45e\u2013445. https:\/\/doi.org\/10.1093\/nar\/29.9.e45","journal-title":"Nucleic Acids Res"},{"key":"4613_CR41","doi-asserted-by":"publisher","first-page":"3798","DOI":"10.3390\/ijms21113798","volume":"21","author":"S Rayego-Mateos","year":"2020","unstructured":"Rayego-Mateos S, Morgado-Pascual JL, Opazo-R\u00edos L et al (2020) Pathogenic pathways and therapeutic approaches targeting inflammation in diabetic nephropathy. IJMS 21:3798. https:\/\/doi.org\/10.3390\/ijms21113798","journal-title":"IJMS"},{"key":"4613_CR42","first-page":"1219","volume":"11","author":"J Song","year":"2019","unstructured":"Song J, Yu J, Prayogo GW et al (2019) Understanding kidney injury molecule 1: a novel immune factor in kidney pathophysiology. Am J Transl Res 11:1219\u20131229","journal-title":"Am J Transl Res"},{"key":"4613_CR43","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.it.2007.09.003","volume":"28","author":"DS Straus","year":"2007","unstructured":"Straus DS, Glass CK (2007) Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. Trends Immunol 28:551\u2013558. https:\/\/doi.org\/10.1016\/j.it.2007.09.003","journal-title":"Trends Immunol"},{"key":"4613_CR44","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00210-018-1469-5","volume":"391","author":"A Tahara","year":"2018","unstructured":"Tahara A, Takasu T (2018) Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice. Naunyn Schmiedebergs Arch Pharmacol 391:395\u2013406. https:\/\/doi.org\/10.1007\/s00210-018-1469-5","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"4613_CR45","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/j.metabol.2004.06.016","volume":"53","author":"M Tanimoto","year":"2004","unstructured":"Tanimoto M, Fan Q, Gohda T et al (2004) Effect of pioglitazone on the early stage of type 2 diabetic nephropathy in KK\/Ta mice. Metabolism 53:1473\u20131479. https:\/\/doi.org\/10.1016\/j.metabol.2004.06.016","journal-title":"Metabolism"},{"key":"4613_CR46","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000320380","volume":"34","author":"JE Toblli","year":"2011","unstructured":"Toblli JE, Cao G, Giani JF et al (2011) Antifibrotic effects of pioglitazone at low doses on the diabetic rat kidney are associated with the improvement of markers of cell turnover, tubular and endothelial integrity, and angiogenesis. Kidney Blood Press Res 34:20\u201333. https:\/\/doi.org\/10.1159\/000320380","journal-title":"Kidney Blood Press Res"},{"key":"4613_CR47","doi-asserted-by":"publisher","first-page":"783780","DOI":"10.3389\/fimmu.2021.783780","volume":"12","author":"D Toobian","year":"2021","unstructured":"Toobian D, Ghosh P, Katkar GD (2021) Parsing the role of PPARs in macrophage processes. Front Immunol 12:783780. https:\/\/doi.org\/10.3389\/fimmu.2021.783780","journal-title":"Front Immunol"},{"issue":"S4","key":"4613_CR48","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/nep.13451","volume":"23","author":"C-W Tung","year":"2018","unstructured":"Tung C-W, Hsu Y-C, Shih Y-H et al (2018) Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology 23(S4):32\u201337. https:\/\/doi.org\/10.1111\/nep.13451","journal-title":"Nephrology"},{"key":"4613_CR49","doi-asserted-by":"publisher","first-page":"106659","DOI":"10.1016\/j.phrs.2023.106659","volume":"188","author":"K Urbanek","year":"2023","unstructured":"Urbanek K, Cappetta D, Bellocchio G et al (2023) Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome. Pharmacol Res 188:106659. https:\/\/doi.org\/10.1016\/j.phrs.2023.106659","journal-title":"Pharmacol Res"},{"key":"4613_CR50","unstructured":"Varghese RT, Jialal I (2023) Diabetic nephropathy. In: StatPearls. StatPearls Publishing, Treasure Island (FL)"},{"key":"4613_CR51","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.compbiolchem.2008.07.014","volume":"32","author":"D Wang","year":"2008","unstructured":"Wang D (2008) Discrepancy between mRNA and protein abundance: insight from information retrieval process in computers. Comput Biol Chem 32:462\u2013468. https:\/\/doi.org\/10.1016\/j.compbiolchem.2008.07.014","journal-title":"Comput Biol Chem"},{"key":"4613_CR52","doi-asserted-by":"publisher","DOI":"10.1155\/2008\/943614","volume":"2008","author":"T Yang","year":"2008","unstructured":"Yang T, Soodvilai S (2008) Renal and vascular mechanisms of thiazolidinedione-induced fluid retention. PPAR Res 2008:943614. https:\/\/doi.org\/10.1155\/2008\/943614","journal-title":"PPAR Res"},{"key":"4613_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.117088","volume":"239","author":"IEM Zabad","year":"2019","unstructured":"Zabad IEM, Amin MN, El-Shishtawy MM (2019) Protective effect of vanillin on diabetic nephropathy by decreasing advanced glycation end products in rats. Life Sci 239:117088. https:\/\/doi.org\/10.1016\/j.lfs.2019.117088","journal-title":"Life Sci"},{"key":"4613_CR54","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1161\/ATVBAHA.108.175687","volume":"28","author":"W-Y Zhang","year":"2008","unstructured":"Zhang W-Y, Schwartz EA, Permana PA, Reaven PD (2008) Pioglitazone inhibits the expression of inflammatory cytokines from both monocytes and lymphocytes in patients with impaired glucose tolerance. Arterioscler Thromb Vasc Biol 28:2312\u20132318. https:\/\/doi.org\/10.1161\/ATVBAHA.108.175687","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4613_CR55","doi-asserted-by":"publisher","first-page":"F639","DOI":"10.1152\/ajprenal.00189.2001","volume":"282","author":"F Zheng","year":"2002","unstructured":"Zheng F, Fornoni A, Elliot SJ et al (2002) Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 282:F639-648. https:\/\/doi.org\/10.1152\/ajprenal.00189.2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"4613_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/8387350","volume":"2019","author":"Q Zhuang","year":"2019","unstructured":"Zhuang Q, Ma R, Yin Y et al (2019) Mesenchymal stem cells in renal fibrosis: the flame of cytotherapy. Stem Cells Int 2019:1\u201318. https:\/\/doi.org\/10.1155\/2019\/8387350","journal-title":"Stem Cells Int"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04613-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04613-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:51:46Z","timestamp":1770882706000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04613-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4613"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04613-x","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experimental procedures were performed following the European animal research laws (European Communities Council Directive 2010\/63\/EU) and complied with the ARRIVE guidelines. The study protocol was approved by the Ethics Committee of the Faculty of Pharmacy at the Comenius University and by the State Veterinary and Food Administration of the Slovak Republic (protocol No: Ro-1636\/17\u2013221, 28 April 2017). All animals were handled by certified investigators and animal keepers.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}